XTRA:EVKChemicals
Evonik Industries (XTRA:EVK) Expands In Vancouver As Fair Value Questions Linger
Evonik Industries (XTRA:EVK) drew investor interest after committing over CAD 150 million to a new lipid-based drug product facility in Vancouver, along with news of interim leadership changes following CEO Christian Kullmann’s unplanned surgery.
Against this backdrop, Evonik Industries’ share price has gained 7.13% over the past 30 days and 11.78% over 90 days, with a year to date share price return of 41.17% and a 1-year total shareholder return of 21.20%. This indicates momentum that...